Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

ACTION, 2021
 
NCT04332107
RCTazithromycinplaceboCOVID 19 outpatientssome concern
171/92 inconclusive
  • inconclusive 1 % increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
The original primary outcome was changed given the lower risk of hospitalization and slower than anticipated enrollment.
Hinks (ATOMIC2), 2021
 
NCT04381962
RCTazithromycinstandard of careCOVID 19 outpatientssome concern
147/148 inconclusive
  • inconclusive 9 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
PRINCIPLE, 2021
 
ISRCTN86534580
RCTazithromycinstandard of careCOVID 19 outpatientssome concern
540/875 inconclusive
  • inconclusive 8 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 6 % decrease in hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).